



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/998,041	11/15/2001	David Botstein	P2730P1C34	4967
35489	7590	09/20/2005	EXAMINER	
HELLER EHRLMAN LLP 275 MIDDLEFIELD ROAD MENLO PARK, CA 94025-3506			WEGERT, SANDRA L	
		ART UNIT		PAPER NUMBER
		1647		

DATE MAILED: 09/20/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	09/998,041	BOTSTEIN ET AL.
	<b>Examiner</b>	<b>Art Unit</b>
	Sandra Wegert	1647

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 23 June 2005.  
 2a) This action is FINAL.                    2b) This action is non-final.  
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 119-123 is/are pending in the application.  
 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.  
 5) Claim(s) \_\_\_\_\_ is/are allowed.  
 6) Claim(s) 119-123 is/are rejected.  
 7) Claim(s) \_\_\_\_\_ is/are objected to.  
 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.  
 10) The drawing(s) filed on 15 November 2001 is/are: a) accepted or b) objected to by the Examiner.  
     Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
     Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)                     |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | Paper No(s)/Mail Date. _____  |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date <u>3/10/05</u> . | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
|  | 6) <input type="checkbox"/> Other: _____                                    |

**Detailed Action**

***Status of Application, Amendments, and/or Claims***

A request for continued examination (RCE) under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. This application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid.

The Response and Amendments, submitted 18 June 2004 and 23 June 2005, have been entered. The Information Disclosure Statement, submitted 10 March 2005, has been entered. Claim 119 is amended. Claim 124 is canceled.

Claims 119-123 are under examination in the Instant Application.

The text of those sections of Title 35, U.S. Code, not included in this action can be found in a prior Office action.

**Withdrawn Objections and/or Rejections**

***Continuity***

The objection to the Specification for not complying with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 119, is *withdrawn*, based on Applicant's arguments (page 3, 23 June 2005). The filing date of the PCT Application (23 June 1999) is considered as the priority date.

**Maintained/New Objections and/or Rejections**

***35 U.S.C. § 101/112, first paragraph-, Lack of Utility, Enablement.***

Claims 119-123 are rejected under 35 U.S.C. 101, as lacking utility. The reasons for this rejection under 35 U.S.C. § 101 are set forth at pages 4-10 of the previous Office Action (18 October 2004). Claims 119-123 are also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility for the reasons set forth in the previous Office Action (18 October 2004), one skilled in the art clearly would not know how to use the claimed invention.

Applicants argue (*Remarks/Arguments*, 23 June 2005, page 3 and throughout) that the data presented in the instant Specification are enabling for the cognate antibody of the polypeptide of SEQ ID NO: 357. They argue that the PRO1182 nucleic acid is a diagnostic marker for lung tumor tissues and point to the results of the gene amplification assay (pages 3 and 8, 23 June 2005; see table 9C of Specification) and the glucose/FFA assay (page 530, Specification).

Applicant's arguments (23 June 2005) have been fully considered but are not found to be persuasive for the following reasons:

In the instant case, the specification provides data showing an indeterminate increase in chromosome number in 3 cancerous lung tumor tissues out of 12 lung tumor tissues tested (see Table 9C). However, there is no evidence regarding whether or not PRO1182 mRNA or polypeptide levels are reliably increased or decreased in a cancer. Furthermore, as discussed in

the previous Office Action (18 October 2004, page 9), what is often seen is a *lack* of correlation between gene amplification and increased peptide levels (Pennica, et al, 1998, Proc. Natl. Acad. Sci., 95: 14717-14722). As discussed by Haynes et al (1998, Electrophoresis, 19: 1862-1871), polypeptide levels cannot be accurately predicted from mRNA levels, and that, according to their results, the ratio varies from zero to 50-fold (page 1863). The literature cautions researchers against drawing conclusions based on *small* changes in transcript gene amplification levels between normal and cancerous tissue. For example, Hu et al. (2003, Journal of Proteome Research 2: 405-412) analyzed 2286 genes that showed a greater than 1-fold difference in mean gene amplification level between breast cancer samples and normal samples in a microarray (p. 408, middle of right column). Hu et al. discovered that, for genes displaying a 5-fold change or less in tumors compared to normal, there was no evidence of a correlation between altered gene amplification and a known role in the disease. However, among genes with a 10-fold or more change in gene amplification level, there was a strong and significant correlation between gene amplification level and a published role in the disease (see discussion section). Regardless of whether there is a correlation between mRNA and protein levels in a sample, the data presented in the instant Application do not show a consistent positive response since only one measurement was made and positive results were found in a minority of cancers.

Given the small increase in gene amplification of PRO1182, in 3 samples of one cancer, and the evidence provided by the current literature, it is clear that one skilled in the art would not assume that a small increase or decrease in gene amplification would correlate with experimentally significant increased or decreased mRNA or polypeptide levels. Further research needs to be done to determine whether the small increase in PRO1182 mRNA in one normal

tissue and one cancer tissue supports a role for the antibody in the cancerous tissue; such a role has not been suggested by the instant disclosure. Such further research requirements make it clear that the asserted utility is not yet in currently available form, i.e., it is not substantial. This further experimentation is part of the act of invention and until it has been undertaken, Applicant's claimed invention is incomplete. As discussed in *Brenner v. Manson*, (1966, 383 U.S. 519, 148 USPQ 689), the court held that:

"The basic quid pro quo contemplated by the Constitution and the Congress for granting a patent monopoly is the benefit derived by the public from an invention with substantial utility", "[u]nless and until a process is refined and developed to this point-where specific benefit exists in currently available form-there is insufficient justification for permitting an applicant to engross what may prove to be a broad field", and,

"a patent is not a hunting license", "[i]t is not a reward for the search, but compensation for its successful conclusion."

Accordingly, the Specification's assertions that the claimed PRO1182 antibodies have utility in the fields of cancer diagnostics and cancer therapeutics are not substantial.

There is no evidentiary support that PRO1182 is involved in the etiology of cancer in the three samples disclosed in the instant Application. Furthermore, as noted above, the increase in PRO1182 mRNA in some samples of one cancerous tissue, and then displaying merely a two-fold increase, points away from its role in a disease. At any rate, 9 negative results combined with three positive results is too incomplete a study to make a conclusion about PRO1182 and cancer. The *specific* function of the PRO1182 polypeptide has not been disclosed by Applicants or by recent research.

As discussed in the previous Office Action (18 October 2004), a 2-fold increase in message is not large and may be less likely to indicate disease (Hu, et al, 2003, Journal of Proteome Research 2:405-412), or may be sufficient (Applicant's Response, page 12). However, the type or magnitude of increase is not at issue in this case. All that is known about the PRO1182 genomic DNA is that it is increased in 3 samples of lung tumor tissue. It cannot be determined what the function of PRO1182 is in the tissues; certainly the tissue provides no clues, and the fact that a minority of tumorous tissues is stained confuses the issue. It is hard to conceive of a specific and substantial utility for a nucleic acid or a peptide encoded by the nucleic acid for which so little consistent data or information is given. For example, what might be the connection between the normal tissue and the cancerous tissue that would provide clues to the PRO peptides function?

In addition, Applicants assert that they are relying on the adipocyte glucose/FFA uptake assay (Example 149) for support of patentable utility (see Response, page 3, 23 June 2005). Applicants explain that the glucose/FFA assay is designed to determine whether a polypeptide is capable of modulating (either positively or negatively), the uptake of glucose or free fatty acids in adipocyte cells. They cite Tafuri et al. (Endocrinology 137(11) : 4706-4712, 1996), Sandouk et al. (endocrinology 133(1): 352-359, 1993), Goldwaser et al. (J Biol Chem 274(37): 26617-26624, 1999), Mueller et al. (Endocrinology 139(2) : 551-558, 1998), and Mueller et al. (Obesity Research 8(7): 530-539, 2000) to support the assertion that increasing glucose uptake by adipocyte cells is a hallmark of a number of therapeutically effective agents. Applicants argue that one of skill in the art would have reasonably accepted that various compounds, such as the

peptide of PRO1182, are capable of modulating glucose uptake and thus have a substantial, practical, real-life utility. They contend that a variety of real-life utilities, such as treatments for glucose uptake-related diseases, including obesity and diabetes, are envisioned for PRO1182 and its cognate antibody, based on the glucose/FFA uptake assay results disclosed in the instant Specification.

Applicant's arguments have been fully considered but are not found to be persuasive. The specification of the instant application teaches that PRO1182 is positive as an *inhibitor* of glucose and FFA uptake by adipocytes (Example 158, page 530). Applicants reiterate this finding by stating at pg 4 of the Response, "As PRO1182 resulted in less than 0.5 the uptake of insulin control, PRO1182 tested positive as an inhibitor of glucose/FFA uptake in adipocyte cells." However, each of the references cited by Applicants teaches that the agents utilized in the assays *enhance* glucose uptake by adipocyte cells, not inhibit glucose uptake as asserted by the instant specification. Disorders such as obesity, diabetes, and hyper- or hypo-insulinemia are characterized by a reduction in the amount of glucose entering all cells, including adipocytes. For example, Tafuri et al. (1996, Endocrinology 137(11) : 4706-4712) and Sandouk et al. (1993, Endocrinology 133(1): 352-359) both describe how troglitazone and poiglitazone are members of the thiazolidinedione class of compounds and have been used to effectively treat non-insulin-dependent diabetes mellitus, the most common form of diabetes. Both compounds have been shown to function, at least in part, by increasing the number of cellular glucose transporters in order to facilitate increased glucose uptake. Goldwaser et al., (1999, J Biol Chem., 274(37): 26617-26624), using the rat adipocyte culture system, showed that vanadium ligand 1-G1u (gamma) HXM potentiates the capacity of free vanadium ions to activate glucose uptake and

glucose metabolism in rat adipocytes in vitro by 4-5 folds and to thus lower blood glucose levels in hyperglycemic rats. Similar assays are commonly used to identify potential anti-diabetic agents and to examine the regulatory mechanisms of important molecules involved in fat cell metabolism (Mueller et al., 1998, Endocrinology, 139(2): 551-558 and Mueller et al., 2000, Obesity Research, 8(7): 530-539).

The studies cited by the Applicants, as well as other studies teach that type II (non-insulin-dependent) diabetes mellitus is a clinical disorder of sugar and fat metabolism caused by an inability of insulin to promote sufficient glucose uptake into adipocyte tissue and striated muscle and to prevent glucose output from the liver. Therefore, as emphasized by Tafuri et al., Sandouk et al., Goldwaser et al., Mueller et al. 1998, and Mueller et al. 2000, one skilled in the art is searching for agents that will enhance glucose uptake into adipocyte cells. However, it is noted again that Applicant asserts the PRO1182 polypeptide inhibits glucose uptake in adipocyte cells. If one skilled in the art were to administer the PRO1182 polypeptide of the instant application to a patient with obesity, diabetes, or hyper- or hypo-insulinemia, the PRO1182 polypeptide would exacerbate the condition. Given the paucity of information, the data do not support the implicit conclusion of the specification that PRO1182 would be useful for the therapeutic treatment of disorders where the inhibition of glucose uptake by adipocytes would be beneficial, including for example, obesity, diabetes or hyper- or hypo-insulinemia. The proposed use of the claimed PRO1182 polypeptides is simply starting points for further research and investigation into potential practical uses of the polypeptides.

Furthermore, Tafuri et al., Sandouk et al., Goldwaser et al., Mueller et al. 1998, and Mueller et al. 2000 teach different methodologies for the measurement of glucose uptake in

adipocyte cells as compared to the glucose assay of the instant specification. For instance, the instant specification teaches that "in a 96 well format, PRO polypeptides to be assayed are added to primary rat adipocytes, and allowed to incubate overnight" (page 4, Response 23 June 2005). Samples are taken at 4 and 16 hours and assayed for glycerol, glucose and FFA uptake. After the 16-hour incubation, insulin is added to the media and allowed to incubate for 4 hours. At this time, a sample is taken and glycerol, glucose and PFA uptake is measured. Media containing insulin without the PRO polypeptide is used as a positive reference control" (pg 512, lines 1-4). However, Sandouk et al. teach that 3T3-F442A cell monolayers were rinsed with PBS and incubated with assay medium for 15 min. Then, 0.5 Ci D-[U-<sup>14</sup>C]glucose was added for 15 min. After this incubation, the medium was aspirated; cells were rinsed, solubilized, neutralized, and counted for radioactivity (pg 353, col 1, first full paragraph). Mueller et al. 2000 disclose that aliquots of adipocytes are incubated with different concentrations of either metformin or vanadium at 24, 48, 72, and 96 hours with or without insulin (pg 532, the bottom of col 1 through col 2). Additionally, the papers cited by Applicants report results for the various samples of the glucose uptake assays. None of the references utilizes the stimulatory and inhibitory scale disclosed in the specification (pg 512, lines 4-6). The instant specification does not report any specific cell numbers or statistical differences and there is no indication in the specification as to how much statistically the PRO1182 inhibited glucose uptake as compared to control.

In conclusion, the PRO1182 antibody of the instant application (made against SEQ ID NO: 357) is not supported by either a credible, specific and substantial ("real-world") asserted utility or a well-established utility. The antibody does not have a substantial utility because basic

Art Unit: 1647

research is required to study the properties and activity of the polypeptide of SEQ ID NO: 357. Until some actual and specific significance can be attributed to the protein identified in the specification as PRO1182, the instant invention is incomplete. In the absence of knowledge of the biological significance of this protein, there is no immediately obvious patentable use for it. Since the instant specification does not disclose a "real world" use for PRO1182, then the claimed invention is incomplete and, therefore, does not meet the requirements of 35 U.S.C. § 101 as being useful.

Because Applicants do not know the function of the PRO1182 polypeptide, *detecting* (by use of the claimed antibodies) the PRO1182 polypeptide has no specific function, since it is not useful to detect a protein for which a function has not yet been identified, and additionally might be expressed in some cancer tissue samples and not others. Since the asserted utility for the PRO1182 antibody is not in currently available form, the asserted utility is not substantial.

### ***Conclusion***

No claims are allowed.

### **Advisory information**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sandra Wegert whose telephone number is (571) 272-0895. The examiner can normally be reached Monday - Friday from 9:00 AM to 5:00 PM (Eastern Time).

If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Brenda Brumback, can be reached at (571) 272-0961.

The fax number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SLW  
12 September 2005



JANET L. ANDRES  
SUPERVISORY PATENT EXAMINER